Champions Oncology, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended April 30, 2014, compared with the year ended April 30, 2013. Although the request metadata refers to “2013 Q4,” this filing is an annual report for fiscal 2014, not a quarterly filing. Amounts below are U.S. dollars; financial-statement amounts are in thousands unless stated otherwise.
Business context
Champions develops and sells oncology technology and services based on implanting human tumors in immune-deficient mice. Its Personalized Oncology Solutions (POS) business serves patients and physicians; its Translational Oncology Solutions (TOS) business serves pharmaceutical and biotechnology companies. TOS generated 80.4% of fiscal 2014 revenue.
Financial performance and liquidity
| Metric | FY2014 | FY2013 | Change |
|---|---|---|---|
| Revenue | $11.550 million | $8.323 million | +38.8% |
| POS revenue | $2.264 million | $2.390 million | -5.3% |
| TOS revenue | $9.286 million | $5.933 million | +56.5% |
| Loss from operations | $6.260 million | $6.221 million | Loss widened $39,000 |
| Net loss | $7.406 million | $6.330 million | Loss widened $1.076 million |
| Basic and diluted loss per share | $0.11 | $0.12 | Improved |
| Cash used in operating activities | $3.433 million | $4.302 million | Use decreased $869,000 |
POS gross margin was negative 21%, versus negative 12% in fiscal 2013, as the company emphasized lower-margin core products. TOS gross margin improved to 63% from 55%. Overall revenue less reported POS and TOS costs of sales was approximately $5.287 million, or 45.8% of revenue, before research and development and other operating expenses.
At April 30, 2014, cash and cash equivalents were $5.891 million, working capital was approximately $3.940 million, and total assets were $8.867 million. Current liabilities were $3.659 million. The filing reports no off-balance-sheet debt or similar obligations; it does report a $2.011 million warrant liability, up from $1.046 million, whose fair-value change increased non-cash expense. Management said available cash was adequate to fund operations at least through fiscal 2015, while noting that additional capital might be needed and could be difficult to raise on acceptable terms. No dividends were anticipated in the foreseeable future.
Material changes, developments, and outlook
- TOS growth drove the increase in total revenue. POS core-product revenue rose 20% to $1.8 million; implants increased 57% to 223, and completed patient studies increased 67% to 87. POS non-core revenue from tumor boards and sequencing fell 55% to $0.5 million.
- Operating expenses rose 22.5% to $17.810 million. Research and development was $2.265 million, sales and marketing $3.155 million, and general and administrative expense $6.127 million. The company attributed G&A growth principally to stock compensation and expansion-related costs.
- Fiscal 2014 net loss included $1.129 million of total other expense, including $965,000 from remeasurement of warrant liability. This remeasurement did not use cash.
- Champions entered a Teva agreement in July 2013 to conduct studies on proprietary compounds; $194,000 of revenue was recognized under it during the year. The agreement provides for conditional milestone payments and potential royalties on commercialized products.
- In December 2013, Champions entered a $1.875 million licensing agreement with Pfizer for use of part of its TumorGraft platform and stated the parties would explore further development and research collaboration. The filing does not clearly state how much of this agreement’s value was recognized as fiscal 2014 revenue.
- The company expected future POS revenue to be driven mainly by core TumorGraft products. It provided no specific revenue, earnings, or cash-flow guidance and said it expected operating losses for the foreseeable future.
Risks, contingencies, and unusual items
- Champions had an accumulated deficit of $38.880 million and reported losses in both years. Management warned that it may need further financing and may not achieve profitability or sustain revenue growth.
- POS economics and adoption remain uncertain: gross margins were negative, tumor implantation and testing can take more than six months, not all tumors grow successfully, and evidence linking mouse responses to patient outcomes was described as limited.
- The TumorGraft platform is proprietary but not patented. Competition, loss of key personnel, and the company’s limited sales history could impede growth.
- Potentially increased FDA oversight of laboratory-developed tests could add costs or delay or prevent sales. The company also depends heavily on its Baltimore laboratory and live mouse population; its Baltimore lease expired in June 2014, and renewal was in progress.
- In January 2014, amendments to investor agreements changed the accounting classification of shares subject to put rights: $16.882 million previously shown as redeemable common stock was reclassified into permanent equity. The agreements retain conditions related to change-of-control or asset-sale events. Related warrants have exercise-price reset provisions and are recorded as liabilities.
- Registration-rights agreements could require cash penalties for filing or effectiveness defaults; potential penalties were not accrued because management did not consider payment probable. A separate $258,000 of deferred revenue related to possible replacement of licensed tumors.
- Three TOS customers each contributed more than 10% of total revenue, with reported revenue of $1.6 million, $1.5 million, and $1.5 million. Stock-based compensation was $2.807 million, and substantial options and warrants create potential dilution.
- The company’s shares traded on the OTC Bulletin Board and were subject to penny-stock rules; the filing warns of thin trading and price volatility. Directors, affiliates, and executive officers beneficially owned approximately 66% of outstanding shares as of June 30, 2014.
The independent auditor gave an unqualified opinion on the financial statements. Management reported that disclosure controls and internal control over financial reporting were effective as of April 30, 2014; the auditor did not express an opinion on internal-control effectiveness.
Important facts for investors to verify
- Whether fiscal 2015 cash needs, burn rate, and financing plans remained consistent with management’s stated runway through at least fiscal 2015.
- Subsequent TOS revenue, customer concentration, contract renewals, and any revenue or cash collected under the Pfizer and Teva arrangements.
- Whether POS tumor take rates, turnaround times, clinical-outcome evidence, and gross margins improved enough to support the strategy.
- The status of the Baltimore laboratory lease and any material FDA or other regulatory developments affecting laboratory-developed tests.
- Current warrant-liability valuation, investor put-right and registration-rights exposure, and the dilutive effect of outstanding options and warrants.
- How the $258,000 deferred-revenue estimate and other revenue-recognition judgments were resolved.